Orthobiologics — products that use the body's own biological processes to enhance healing — represent one of the highest-growth and highest-margin segments in the orthopedics market. Bone graft substitutes, platelet-rich plasma systems, demineralized bone matrix, growth factors, and emerging cell-based therapies collectively address the clinical challenge of bone and soft tissue healing in an aging population with increasing comorbidities.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Bone Graft Substitute Market
• Demineralized Bone Matrix
• Platelet-Rich Plasma Systems
• Growth Factors — BMP-2, BMP-7
• Stem Cell and Cell-Based Therapies
• Bioactive Implant Surfaces
• Regulatory Pathway for Biologics
Table of Contents
1. Executive Summary
2. Market Overview
3. Bone Graft Substitute Market
4. Demineralized Bone Matrix
5. Platelet-Rich Plasma Systems
6. Growth Factors — BMP-2, BMP-7
7. Stem Cell and Cell-Based Therapies
8. Bioactive Implant Surfaces
9. Regulatory Pathway for Biologics
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Suppliers — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Regional Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Aesculap
Arthrex
DePuy Synthes
Enovis
Globus Medical
NuVasive
Smith & Nephew
Stryker
Wright Medical
Zimmer Biomet
